Gilead Sciences, Inc.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada,…
Drug Manufacturers - General
US, Foster City [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
1
Financial Health
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Current Ratio | -26.04 | 1.08 | 1.46 | |
| Debt/Assets | n.A. | n.A. | n.A. | |
| Debt/Equity | n.A. | n.A. | n.A. | |
| Net Debt/EBITDA | 13.65 | 6.84 | 6.02 | |
| Naive Interpretation | member | |||
2
Per Share
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | -22.84 | 14.06 | 18.23 | |
| Cash | -16.52 | 4.86 | 5.82 | |
| Capex | 51.12 | -0.08 | -0.17 | |
| Free Cash Flow | 8.28 | 1.70 | 1.57 | |
| Revenue | -5.95 | 5.36 | 5.70 | |
| Naive Interpretation | member | |||
3
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Margin | -1.65 | 0.77 | 0.78 | |
| Operating Margin | -2.25 | 0.34 | 0.35 | |
| ROA | 222.05 | -0.07 | 0.02 | |
| ROE | 278.50 | -0.24 | 0.06 | |
| ROIC | 11.30 | 0.05 | 0.05 | |
| Naive Interpretation | member | |||
4
Valuation
The "Valuation Entry" for the Focus of GILD is permitted for members.
5
Growth
The "Growth Entry" for the Focus of GILD is permitted for members.
6
Leverage & Liquidity